0.3832

2.68% -0.0119

X 4 Pharmaceuticals Inc (XFOR)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

X 4 Pharmaceuticals Inc stock is traded at $0.3832, with a volume of 287.02K. It is down -2.68% in the last 24 hours and down -35.93% over the past month. X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Previous Close:

$0.3951

Open:

$0.4075

24h Volume:

287.02K

Relative Volume:

0.07

Market Cap:

$66.91M

Revenue:

Net Income/Loss:

$-16.76M

P/E Ratio:

-4.79

EPS:

-0.08

Net Cash Flow:

$-132.97M

1W Performance:

-15.27%

1M Performance:

-35.93%

6M Performance:

-41.69%

1Y Performance:

-61.93%

1-Day Range:

$0.3801

$0.4182

1-Week Range:

$0.3607

$0.4599

52-Week Range:

$0.2612

$1.60

X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile

Name

X 4 Pharmaceuticals Inc

Sector

Healthcare (1188)

Industry

Biotechnology (679)

Phone

857-529-8300

Address

61 NORTH BEACON STREET, BOSTON, MA

Employee

143

Twitter

@x4pharma

Next Earnings Date

2024-11-13

Latest SEC Filings

XFOR's Discussions on Twitter

Compare XFOR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XFOR X 4 Pharmaceuticals Inc	0.3832	66.91M	0	-16.76M	-132.97M	-0.08
VRTX Vertex Pharmaceuticals Inc	488.63	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	688.49	75.07B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	634.75	37.96B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	242.35	31.79B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	112.69	27.34B	3.30B	-501.07M	1.03B	-2.1146

X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-12-23	Downgrade	B. Riley Securities	Buy → Neutral
Aug-30-23	Resumed	B. Riley Securities	Buy
Dec-22-22	Initiated	Cantor Fitzgerald	Overweight
Dec-12-22	Initiated	Piper Sandler	Overweight
Dec-23-19	Initiated	Oppenheimer	Outperform
Dec-18-19	Initiated	ROTH Capital	Buy
Dec-09-19	Upgrade	Citigroup	Neutral → Buy
Dec-05-19	Initiated	B. Riley FBR	Buy
Jun-07-19	Initiated	Stifel	Buy
Jun-05-19	Initiated	Cowen	Outperform

View All

X 4 Pharmaceuticals Inc Stock (XFOR) Latest News

11:15 AM

Layoff Tracker: CRISPR, Cytiva Laying Off Employees - BioSpace

11:15 AM

07:51 AM

How pharma CEO pay shifted for these 4 companies last year - PharmaVoice

07:51 AM

03:25 AM

Atria Wealth Solutions Inc. Buys New Position in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) - Defense World

03:25 AM

Feb 28, 2025

President and CEO Polymeropoulos Mihael Hristos bought $47,600 worth of shares (10,000 units at $4.76), increasing direct ownership by 0.43% to 2,361,730 units (SEC Form 4) - Quantisnow

Feb 28, 2025

ANI Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 28, 2025

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS) - Yahoo Finance

Feb 28, 2025

The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease - Quantisnow

Feb 28, 2025

Feb 27, 2025

Earnings call transcript: Xenon Pharmaceuticals Q4 2024 sees slight EPS beat - Investing.com

Feb 27, 2025

Financial Survey: X4 Pharmaceuticals (NASDAQ:XFOR) & Tourmaline Bio (NASDAQ:TRML) - Defense World

Feb 27, 2025

Feb 26, 2025

President and CEO Polymeropoulos Mihael Hristos bought $47,650 worth of shares (10,000 units at $4.76), increasing direct ownership by 0.43% to 2,341,730 units (SEC Form 4) - Quantisnow

Feb 26, 2025

Popular lemonade recalled by FDA for cancer-linked chemical - New York Post

Feb 26, 2025

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update - Business Wire

Feb 26, 2025

Feb 25, 2025

President and CEO Polymeropoulos Mihael Hristos bought $44,640 worth of shares (10,000 units at $4.46), increasing direct ownership by 0.43% to 2,331,730 units (SEC Form 4) - Quantisnow

Feb 25, 2025

Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences - Business Wire

Feb 25, 2025

Feb 24, 2025

SVP, CFO & Treasurer Moran Kevin Patrick bought $8,779 worth of shares (2,000 units at $4.39), increasing direct ownership by 0.57% to 355,763 units (SEC Form 4) - Quantisnow

Feb 24, 2025

3 Pharmaceutical Stocks With Blockbuster Drug Potential - TradingView

Feb 24, 2025

Licensing For Innovation: A Decade Of Pharma Product Deals - Insights

Feb 24, 2025

Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 - Business Wire

Feb 24, 2025

DeFloria Receives Investigational New Drug Application Clearance from FDA for Phase 2 Clinical Trial of AJA001, an Oral Cannabinoid Drug Being Developed for the Treatment of Autism Spectrum Disorder (ASD) - PR Newswire

Feb 24, 2025

Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S" - Morningstar

Feb 24, 2025

Feb 20, 2025

SVP, CFO & Treasurer Moran Kevin Patrick was granted 125,000 shares, increasing direct ownership by 55% to 353,763 units (SEC Form 4) - Quantisnow

Feb 20, 2025

Feb 19, 2025

X4 Pharmaceuticals, Taiba to Distribute Xolremdi in Select Middle East Countries -February 19, 2025 at 10:56 am EST - Marketscreener.com

Feb 19, 2025

X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries - Marketscreener.com

Feb 19, 2025

X4 Pharmaceuticals and Taiba Rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI®? in WHIM Syndrome in Select Middle East Countries - Marketscreener.com

Feb 19, 2025

Feb 16, 2025

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Short Interest Up 22.6% in January - MarketBeat

Feb 16, 2025

Feb 15, 2025

Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Yahoo Finance

Feb 15, 2025

Feb 14, 2025

X4 pharmaceuticals chief commercial officer Mark Baldry acquires $19,251 in stock By Investing.com - Investing.com South Africa

Feb 14, 2025

X4 pharmaceuticals chief commercial officer Mark Baldry acquires $19,251 in stock - Investing.com India

Feb 14, 2025

Feb 13, 2025

HC Wainwright Cuts Earnings Estimates for X4 Pharmaceuticals - MarketBeat

Feb 13, 2025

Fierce Biotech Layoff Tracker 2025: Encoded trims 29% of team; Inventiva halves staff - Fierce Biotech

Feb 13, 2025

Feb 12, 2025

SG Americas Securities LLC Increases Stock Holdings in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) - Defense World

Feb 12, 2025

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 - Business Wire

Feb 12, 2025

Feb 11, 2025

Finance Watch: Third Harmonic, Q32 Bio Cut Jobs To Focus On Lead Assets - News & Insights

Feb 11, 2025

FY2027 EPS Forecast for X4 Pharmaceuticals Cut by Analyst - Defense World

Feb 11, 2025

FY2028 Earnings Estimate for XFOR Issued By HC Wainwright - Defense World

Feb 11, 2025

Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion - Business Wire

Feb 11, 2025

Feb 10, 2025